Last reviewed · How we verify

Bupivacaine, epinephrine, dexamethasone, and clonidine

Tufts Medical Center · Phase 2 active Small molecule

Bupivacaine, epinephrine, dexamethasone, and clonidine is a Local anesthetic combination with adjuvants Small molecule drug developed by Tufts Medical Center. It is currently in Phase 2 development for Regional anesthesia and analgesia (Phase 2 investigational). Also known as: Standard Preparation.

This combination provides local anesthesia via bupivacaine while epinephrine prolongs duration, dexamethasone reduces inflammation, and clonidine enhances analgesia through alpha-2 adrenergic receptor activation.

This combination provides local anesthesia via bupivacaine while epinephrine prolongs duration, dexamethasone reduces inflammation, and clonidine enhances analgesia through alpha-2 adrenergic receptor activation. Used for Regional anesthesia and analgesia (Phase 2 investigational).

At a glance

Generic nameBupivacaine, epinephrine, dexamethasone, and clonidine
Also known asStandard Preparation
SponsorTufts Medical Center
Drug classLocal anesthetic combination with adjuvants
TargetVoltage-gated sodium channels (bupivacaine); alpha-2 adrenergic receptors (clonidine); glucocorticoid receptor (dexamethasone)
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhasePhase 2

Mechanism of action

Bupivacaine is a long-acting local anesthetic that blocks sodium channels in nerve fibers. Epinephrine causes vasoconstriction to prolong drug residence time at the injection site. Dexamethasone, a corticosteroid, reduces local inflammation and may extend anesthetic duration. Clonidine, an alpha-2 agonist, enhances analgesia and prolongs the sensory block when added to local anesthetics.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bupivacaine, epinephrine, dexamethasone, and clonidine

What is Bupivacaine, epinephrine, dexamethasone, and clonidine?

Bupivacaine, epinephrine, dexamethasone, and clonidine is a Local anesthetic combination with adjuvants drug developed by Tufts Medical Center, indicated for Regional anesthesia and analgesia (Phase 2 investigational).

How does Bupivacaine, epinephrine, dexamethasone, and clonidine work?

This combination provides local anesthesia via bupivacaine while epinephrine prolongs duration, dexamethasone reduces inflammation, and clonidine enhances analgesia through alpha-2 adrenergic receptor activation.

What is Bupivacaine, epinephrine, dexamethasone, and clonidine used for?

Bupivacaine, epinephrine, dexamethasone, and clonidine is indicated for Regional anesthesia and analgesia (Phase 2 investigational).

Who makes Bupivacaine, epinephrine, dexamethasone, and clonidine?

Bupivacaine, epinephrine, dexamethasone, and clonidine is developed by Tufts Medical Center (see full Tufts Medical Center pipeline at /company/tufts-medical-center).

Is Bupivacaine, epinephrine, dexamethasone, and clonidine also known as anything else?

Bupivacaine, epinephrine, dexamethasone, and clonidine is also known as Standard Preparation.

What drug class is Bupivacaine, epinephrine, dexamethasone, and clonidine in?

Bupivacaine, epinephrine, dexamethasone, and clonidine belongs to the Local anesthetic combination with adjuvants class. See all Local anesthetic combination with adjuvants drugs at /class/local-anesthetic-combination-with-adjuvants.

What development phase is Bupivacaine, epinephrine, dexamethasone, and clonidine in?

Bupivacaine, epinephrine, dexamethasone, and clonidine is in Phase 2.

What are the side effects of Bupivacaine, epinephrine, dexamethasone, and clonidine?

Common side effects of Bupivacaine, epinephrine, dexamethasone, and clonidine include Hypotension, Bradycardia, Dizziness, Nausea, Local injection site reactions.

What does Bupivacaine, epinephrine, dexamethasone, and clonidine target?

Bupivacaine, epinephrine, dexamethasone, and clonidine targets Voltage-gated sodium channels (bupivacaine); alpha-2 adrenergic receptors (clonidine); glucocorticoid receptor (dexamethasone) and is a Local anesthetic combination with adjuvants.

Related